We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Resources to support the commissioning and delivery of tier 2 behavioural weight management services for children, families and adults.
Insights from new evidence on the relationship between excess weight and coronavirus (COVID-19).
A resource to support local authorities, NHS commissioners and providers, voluntary and community sector organisations to take action to reduce obesity.
Practical advice and tools to support health and care professionals have conversations about weight management with children and their families.
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
Healthcare professionals should be aware of the potential risk of pulmonary aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who undergo surgery or procedures with general anaesthesia or deep sedation.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).